Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pfizer
>
Heard about Vascepa launch?
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 4534115"]Vascepa better efficacy than Lovaza? Really? No head to head studies but you be the judge.</p><p><br /></p><p>Lovaza studies: 45% reduction in very high TG from an 816 mg/dl baseline. 29.5% reduction in high TG from a 268 mg/dl baseline.</p><p><br /></p><p>Vascepa studies: 27% reduction in very high TG from a 680 mg\dl baseline.</p><p><br /></p><p>So Lovaza lowered TG by about the same percentage from a much lower baseline TG value, 268 v. 680. Interesting. I call bullshit on any superior efficacy claim. This data is from both PI's.</p><p><br /></p><p>LDL? 25% of patients were taking statins in the Vascepa trials. So not a mono therapy study. The Tricor PI shows a 45% increase in LDL for very high TG patients. Lovaza does as well. These were mono therapy studies with no statin background use. You cannot lower very high TG's, VLDL, and not see an increase in LDL without the aid of a statin. This is lipid metabolism 101.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 4534115"]Vascepa better efficacy than Lovaza? Really? No head to head studies but you be the judge. Lovaza studies: 45% reduction in very high TG from an 816 mg/dl baseline. 29.5% reduction in high TG from a 268 mg/dl baseline. Vascepa studies: 27% reduction in very high TG from a 680 mg\dl baseline. So Lovaza lowered TG by about the same percentage from a much lower baseline TG value, 268 v. 680. Interesting. I call bullshit on any superior efficacy claim. This data is from both PI's. LDL? 25% of patients were taking statins in the Vascepa trials. So not a mono therapy study. The Tricor PI shows a 45% increase in LDL for very high TG patients. Lovaza does as well. These were mono therapy studies with no statin background use. You cannot lower very high TG's, VLDL, and not see an increase in LDL without the aid of a statin. This is lipid metabolism 101.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pfizer
>
Heard about Vascepa launch?
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Pfizer
>
Heard about Vascepa launch?
>